Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Adverse effects · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
Botulinum toxin injection may leads to lower adverse effects compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events, reported as "negative experiences" · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
It is very uncertain whether radiotherapy changes adverse events, reported as "negative experiences" compared with botulinum toxin (very low certainty).
1 finding from 1 review
Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Moderate
Proportion of participants with endophthalmitis · people with bilateral age‐related cataracts (NRSs)
2 findings from 1 review
Complications · people with bilateral age‐related cataracts (NRSs)
It is very uncertain whether ISBCS changes complications compared with DSBCS (very low certainty).
2 findings from 1 review
Total costs per participant · people with bilateral age‐related cataracts (NRSs)
2 findings from 1 review
Total costs per QALY · people with bilateral age‐related cataracts (NRSs)
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
BCDVA · people with bilateral age‐related cataracts (NRSs)
The review found no eligible studies for this question.
2 findings from 1 review
Patient‐reported outcome measures (PROMs) · people with bilateral age‐related cataracts (NRSs)
The review found no eligible studies for this question.
2 findings from 1 review
Refraction NOT within 1.0 dioptres of target · people with bilateral age‐related cataracts (NRSs)
ISBCS showed no clear difference in refraction NOT within 1.0 dioptres of target compared with DSBCS (moderate certainty).
2 findings from 1 review
Pain (VAS, PRTEE) translated to 0 to 10, where 0 is no pain · lateral elbow pain
1 finding from 1 review
Disability DASH scale. Scale from: 0 to 100. ( · lateral elbow pain
1 finding from 1 review
Treatment success (> 25% improvement in pain or function) · lateral elbow pain
It is very uncertain whether autologous blood or PRP changes treatment success (> 25% improvement in pain or function) compared with placebo at 3 months' follow‐up (very low certainty).
1 finding from 1 review
Health‐related Quality of Life Not measured · lateral elbow pain
1 finding from 1 review
Relief of pain · lateral elbow pain
1 finding from 1 review